Start with your facts
A legal review may examine an alleged failure to warn or another theory of responsibility. A medicine’s risks and a diagnosis after use do not, by themselves, establish liability.
Brand and generic products require careful identification
Gabapentin may be supplied by different manufacturers over time. Legal rules can differ for brand-name and generic products. Pharmacy records identifying each fill help counsel determine which issues need analysis; no manufacturer should be assumed responsible from the drug name alone.
Research, allegations and court findings are different
A study can raise questions without establishing causation. A lawsuit sets out allegations that may be disputed. Neither is the same as a court determination that a product caused an injury.
Do not confuse different types of settlements
Historical drug marketing or pricing matters address different allegations from an individual personal-injury claim. A headline about a past settlement does not establish a dementia compensation fund or mean you are entitled to payment.
Deadlines need individual attention
Time limits depend on the jurisdiction, claim, injury and other facts. Contact counsel promptly. Visiting this site, preparing for a call or making an inquiry does not preserve a filing deadline.
What happens after you call?
Be ready to explain your medication history, diagnosis, state and key dates. JAG Legal Group or appropriate counsel can assess whether further investigation is warranted. Representation requires a written engagement agreement, which addresses scope and any fees and expenses. No recovery is guaranteed.
Check the source behind litigation news
The November federal litigation guide explains the scope of the November 2 JPML report. An active federal MDL list does not answer whether a state case exists. No research prescription-count or age category should be treated as a universal legal cutoff.
An actual complaint still contains allegations
Our Seifers complaint guide links to a court-stamped September filing discussed in November. It helps distinguish an individual filing from a court finding, settlement or coordinated-program order. The products and facts of that case do not decide someone else's eligibility.
